Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Alan K. Burnett, MD, Robert K. Hills, DPhil, David Grimwade, MD, Anthony H. Goldstone, MD, Ann Hunter, MD, Don Milligan, MD, Archie G. Prentice, MD, Nigel H. Russell, MD, Keith Wheatley, DPhil

Blood (2007) 110 (11): 589.

https://doi.org/10.1182/blood.V110.11.589.589

Published: 2007

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, MD, Anthony H. Goldstone, DM, Donald Milligan, FRCP, Ann Hunter, FRCP, Archie G. Prentice, FRCP, Nigel H. Russell, MD, Brenda Gibson, FRCP, Keith Wheatley, DPhil, Robert K. Hills, MA, MSc, DPhil

Blood (2006) 108 (11): 13.

https://doi.org/10.1182/blood.V108.11.13.13

Published: 2006

Journal Articles

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

Alan K. Burnett, MD, FRCPath, FRCP, Robert K. Hills, MA, MSc, DPhil, Keith Wheatley, DPhil, Anthony H. Goldstone, MRCP, MRCPath, FRCP, Archie G. Prentice, MB, ChB, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath

Blood (2006) 108 (11): 18.

https://doi.org/10.1182/blood.V108.11.18.18

Published: 2006

Journal Articles

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Keith Wheatley, DPhil, Cassey L. Brookes, MSc, Robert K. Hills, DPhil, Anthony H. Goldstone, FRCP, Donald W. Milligan, MD, Archie G. Prentice, Anthony V. Moorman, PhD, Alan K. Burnett

Blood (2005) 106 (11): 674.

https://doi.org/10.1182/blood.V106.11.674.674

Published: 2005

Journal Articles

Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.

Alan K. Burnett, MD, Donald W. Milligan, MD, Archie G. Prentice, MB, Anthony H. Goldstone, MD, Mary F. McMullin, MD, Robert K. Hills, PhD, Keith Wheatley, PhD

Blood (2005) 106 (11): 543.

https://doi.org/10.1182/blood.V106.11.543.543

Published: 2005

Journal Articles

Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.

Alan K. Burnett, MD, Donald Milligan, MD, Archie G. Prentice, MD, Anthony H. Goldstone, MD, Mary F. McMullin, MD, Keith Wheatley, PhD

Blood (2004) 104 (11): 872.

https://doi.org/10.1182/blood.V104.11.872.872

Published: 2004

Journal Articles

The Impact of Transplant in AML in 2nd CR: A Prospective Study of 741 in the MRC AML 10 and 12 Trials.

Alan K. Burnett, MD, Robert K. Hills, PhD, Anthony H. Goldstone, MD, Donald Milligan, MD, Archie G. Prentice, MD, Ian Hann, MD, David Webb, MD, Brenda Gibson, MD, Keith Wheatley, PhD

Blood (2004) 104 (11): 620.

https://doi.org/10.1182/blood.V104.11.620.620

Published: 2004

Journal Articles

Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.

Alan K. Burnett, MD, Donald Milligan, MD, Robert K. Hills, PhD, Anthony H. Goldstone, MD, Archie G. Prentice, MD, Keith Wheatley, PhD, David C. Webb, MD, Brenda Gibson, MD

Blood (2004) 104 (11): 1794.

https://doi.org/10.1182/blood.V104.11.1794.1794

Published: 2004

Journal Articles

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

William J. Kell, Alan K. Burnett, Raj Chopra, John A. L. Yin, Richard E. Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G. Prentice, Donald W. Milligan

Blood (2003) 102 (13): 4277–4283.

https://doi.org/10.1182/blood-2003-05-1620

Published: 2003

NARROW

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.

Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.

The Impact of Transplant in AML in 2nd CR: A Prospective Study of 741 in the MRC AML 10 and 12 Trials.

Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only